Story

Carl Zeiss Meditec Reports Revenue Decline on China Weakness, Lowers Profit Margin

ENTHMSVIIDZHZH-TWJAKOHI
Aug 6, 20261 min read
Carl Zeiss Meditec Reports Revenue Decline on China Weakness, Lowers Profit Margin
Text size
Background

German medical technology company Carl Zeiss Meditec AG (ETR:AFX) reported a revenue decline and significant margin pressure for the first nine months of its fiscal year, primarily driven by challenges in the Chinese market and unfavorable currency movements.

Financial Performance Details

For the nine-month period, the company's revenue fell by 2.9% year-over-year to €1.55 billion, according to its latest financial release. On a currency-adjusted basis, revenue was reportedly flat compared to the prior-year period.

The company's adjusted EBITA margin saw a notable contraction, falling to 8.0% from 11.1% in the same period last year. Carl Zeiss Meditec attributed the decline to negative currency effects and lower sales of consumable products.

Segment Challenges in Asia-Pacific

The downturn was most pronounced in the company's ophthalmology business, which faced weak demand in China. Performance was further hampered by the withdrawal of a bifocal intraocular lens product from a procurement tender in the country, leading to inventory returns.

Sample IUX Markets – In-articleAd

The refractive laser business also experienced a decline, which the company linked to lower surgical volumes and a more conservative investment climate for new equipment, particularly in the Asia-Pacific region. In contrast, the microsurgery division posted growth, supported by strong deliveries of neurosurgery microscopes.

Outlook and Goodwill Impairment

Looking ahead to its 2025/26 fiscal year, Carl Zeiss Meditec provided the following guidance:

  • Full-year revenue is projected to be between €2.15 billion and €2.20 billion.
  • Adjusted EBITA margin is forecast to be in the range of 8% to 10%.

The company also announced it anticipates recording a goodwill impairment charge of approximately €150 million on its ophthalmology strategic business unit in the fourth quarter of the 2025/26 fiscal year.

Read next

More on Stocks
Back to latest news

LATEST